Losartán: Más de 25 años de evidencia

Instagram:⁠ ⁠@dr.gilbertogarciabernal⁠⁠Infografías en X:⁠ ⁠@DoctorGilbertoG⁠Sex differences in efficacy of angiotensin receptor blockers on kidney and cardiovascular outcomes among individuals with type 2 diabetes and diabetic kidney disease: post hoc analyses of the RENAAL and IDNT trials (Diabetologia, 2025)Los ARA II brindan protección renal equivalente en ambos sexos, pero su beneficio cardiovascular es exclusivo para los hombres, no observándose protección en las mujeres. Oral Losartan Treatment Improves Microvascular Endothelial Function via Nitric Oxide-Dependent Mechanisms in Women With a History of Preeclampsia (Am J Hypertens, 2025)El losartán mejora la función endotelial microvascular en mujeres con antecedentes de preeclampsia al potenciar la dilatación dependiente de óxido nítrico y reducir la sensibilidad vasoconstrictora a la angiotensina II. Estos beneficios actúan de forma independiente a los cambios en la presión arterial.High- Versus Low-dose Losartan and Serum Potassium: An Analysis From HEAAL (J Card Fail, 2023)High- versus low-dose losartan and uric acid: An analysis from HEAAL (J Cardiol, 2023)Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70 (Cells, 2021) Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial (Eur J Heart Fail, 2021)Losartan: Comprehensive Profile (Profiles Drug Subst Excip Relat Methodol, 2015)Atenolol versus Losartan in Children and Young Adults with Marfan’s Syndrome (N Engl J Med, 2014)Adverse events in HEAAL: when to hold and when to fold (Eur J Heart Fail, 2012)Pharmacokinetic evaluation of losartan (Expert Opin Drug Metab Toxicol, 2011)HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure— lessons learnt from a decade of trials (Eur J Heart Fail, 2010)Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial (Lancet, 2009)All clinical trials are not created equal: The dilemma of HEAAL (Eur J Heart Fail, 2008)Losartan: lessons learned from the RENAAL study (Expert Opin Pharmacother, 2006)Losartan and End-Organ Protection—Lessons from the RENAAL Study (Clin Cardiol, 2005)Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: New lessons from the RENAAL Study (Kidney Int, 2005)Clinical Pharmacokinetics of Losartan (Clin Pharmacokinet, 2005)Dialysis delayed is death prevented: A clinical perspective on the RENAAL study (Kidney Int, 2003)Losartan In Diabetic Nephropathy (Drugs, 2003)Recent Advances in Management of Type 2 Diabetes and Nephropathy: Lessons From the RENAAL Study (Am J Kidney Dis, 2003)Effect of Losartan on Microalbuminuria in Normotensive Patients with Type 2 Diabetes Mellitus (Ann Intern Med, 2003)Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial (Lancet, 2002)Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol (Lancet, 2002)Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (N Engl J Med, 2001)The Role of Losartan in the Management of Patients with Heart Failure (Clin Ther, 2001) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II (Lancet, 2000) Evaluation of the Losartan in Hemodialysis (ELHE) Study (Kidney Int, 1998) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) (Lancet, 1997)